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Discovery of a C3(H2 O) uptake pathway has led to renewed interest in this alternative
pathway triggering form of C3 in human biospecimens. Previously, a quantifiable method
to measure C3(H2 O), not confounded by other complement activation products, was
unavailable. Herein, we describe a sensitive and specific ELISA for C3(H2 O). We initially
utilized this assay to determine baseline C3(H2 O) levels in healthy human fluids and
to define optimal sample storage and handling conditions. We detected ∼500 ng/ml
of C3(H2 O) in fresh serum and plasma, a value substantially lower than what was
predicted based on previous studies with purified C3 preparations. After a single
freeze-thaw cycle, the C3(H2 O) concentration increased 3- to 4-fold (∼2,000 ng/ml).
Subsequent freeze-thaw cycles had a lesser impact on C3(H2 O) generation. Further,
we found that storage of human sera or plasma samples at 4◦ C for up to 22 h did not
generate additional C3(H2 O). To determine the potential use of C3(H2 O) as a biomarker,
we evaluated specimens from patients with inflammatory-driven diseases. C3(H2 O)
concentrations were moderately increased (1.5- to 2-fold) at baseline in sera from active
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients compared
to healthy controls. In addition, upon challenge with multiple freeze-thaw cycles or
incubation at 22 or 37◦ C, C3(H2 O) generation was significantly enhanced in SLE and RA
patients’ sera. In bronchoalveolar lavage fluid from lung-transplant recipients, we noted
a substantial increase in C3(H2 O) within 3 months of acute antibody-mediated rejection.
In conclusion, we have established an ELISA for assessing C3(H2 O) as a diagnostic and
prognostic biomarker in human diseases.
Keywords: complement, C3, human, autoimmunity, ELISA, C3(H2O), biomarker

INTRODUCTION
The complement system is a well-established component of innate immunity and an instructor of
adaptive immunity. An important function of the complement system is to identify and opsonize
targets, including microbes, immune complexes, apoptotic cells and necrotic tissue, to facilitate
their “safe” removal. Complement activation occurs primarily through three pathways, the classical
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guidance as to how human samples should be handled and stored
in clinical and laboratory settings.

(CP), lectin (LP), and alternative (AP). While the CP and LP
have specific triggers (antibodies and lectins, respectively), the
AP is thought to be independently engaged by the spontaneous
activation of C3 to a form with a cleaved thioester bond (1, 2).
The prevailing hypothesis is that this occurs by the spontaneous,
low-level hydrolysis of the internal thioester bond in native C3
in the fluid phase (3–5). Within microseconds this form of C3
becomes covalently bound to a target (such as a microbe or cell)
or interacts with water to form C3(H2 O) (4). C3(H2 O) can then
bind factor B (FB) after which factor D cleaves FB to Bb and
Ba. The C3 converting enzyme or convertase, C3(H2 O)Bb, then
generates C3b from C3 to initiate AP activity on a nearby target
(4, 6). To regulate this system, factor H (FH) binds C3(H2 O)
and the serine protease factor I (FI) can then cleave it to a form
that cannot amplify the cascade (2, 7, 8). Since C3(H2 O) may
be a trigger for complement activation at sites of cellular injury,
degeneration or autoimmune attack, a simple, quantitative and
specific assay for this form of C3 could provide insights into how
the complement system functions in human disease.
Undesirable and excessive activation of C3 is a feature of
multiple autoimmune- and inflammatory-driven diseases (9,
10). Interest in C3(H2 O) in disease processes has recently
been renewed due to the discovery of the intracellular
complement system (ICS) whose dysfunction is increasingly
associated with impaired cellular metabolism, debris clearance
and autoimmunity (11–19). In a follow-up report to the
identification of the ICS, we made an additional key observation
of a process in which C3(H2 O) is loaded into the cell interior
where it can be stored or recycled back out of the cell (20).
Importantly, this represents an exogenous shuttling pathway in
which the transported C3(H2 O) could modulate immune cell
functions, such as IL-6 secretion (20). Thus, C3(H2 O) generation
is functionally relevant as a trigger for the AP in the extracellular
space (3, 4) and, once generated, it can also be loaded into cells to
play a role in the ICS (20).
We hypothesize that C3(H2 O) is a major player in cellular
homeostasis whose upregulation may serve as a biomarker of
inflammatory processes. Prior ELISA assessments of C3(H2 O)
were confounded by reactivity to additional fragments, especially
C3a (21, 22). Herein, we describe the development of an ELISA
that is specific for C3(H2 O). The selectivity is based, first, on
the capture of the conformationally altered structure of C3(H2 O)
and, second, by detection of the C3a domain. Using this ELISA,
we have initially characterized the specificity of this assay,
optimized specimen handling and quantified levels in human
serum and plasma from healthy donors. Additionally, we have
determined levels of C3(H2 O) that are generated under various
potential modifiers and in disease situations that will provide

MATERIALS AND METHODS
Antibodies and Proteins
Purified C3, C3b, C3a, iC3b, FH, and FI were obtained
from Complement Technologies. Complement receptor 1 (CR1;
CD35) was from Avant Immunotherapeutics. The mouse antiC3b/iC3b [clone 3E7, (23) and specificity for iC3b confirmed in
(24)] was a generous gift from Dr. Ronald Taylor (University
of Virginia Health Sciences Center) and was also purchased
from MilliporeSigma. Rabbit anti-human C3a (A218) and
goat anti-human C3 (A213) polyclonal antibodies (pAbs) were
also purchased from Complement Technologies. Chicken antihuman C3 (GW20073F) pAb was obtained from MilliporeSigma.

Sample Processing
Whole blood was collected by venipuncture in commercial blood
collection tubes (BD Biosciences Vacutainer). Serum samples
were allowed to clot for 30 min at RT prior to centrifugation
at 2,000 x g for 5 min. Plasma samples were centrifuged at
RT immediately at 2,000 x g for 10 min. Samples were either
evaluated immediately (fresh) or stored in aliquots at −80◦ C
until use. Bronchoalveolar lavage (BAL) fluid was obtained from
lung transplant recipients by instilling phosphate-buffered saline
into the airway via a bronchoscope followed by aspiration. The
fluid was transported at 4◦ C after which cells were separated by
centrifugation at 500 x g for 10 min at 4◦ C. BAL samples were
stored at −80◦ C until use.

C3 Handling and Preparation
To prepare a C3(H2 O) analog known as C3(MA), we treated
purified C3 with methylamine to hydrolyze the thioester bond (3,
20). Briefly, purified C3 was incubated with 0.4 M methylamine
hydrochloride (Sigma Aldrich) and 0.1 M Tris pH 8.0 for 1 h
at 37◦ C. Another analog, C3(KBr), was generated by treatment
of purified C3 with 2 M potassium bromide for 3 h at 37◦ C
(25). Freeze/thaw cycles of serum and plasma were performed
by rapidly thawing 100 µl samples at 37◦ C in a water bath.
Immediately after thawing, the C3 was placed on ice and returned
to the −80◦ C freezer for 15 min. Freeze/thaw cycles of purified
C3 were performed by thawing 100 µl aliquots of 1 mg/ml C3 at
22◦ C, followed by freezing at −80◦ C.

ELISA Protocol
Maxisorp 96-well ELISA plates were coated with 100 µl/well
of 2 µg/ml 3E7 [anti-C3b/iC3b antibody characterized in (23)]
diluted in PBS overnight at 4◦ C. The plates were washed 3x
with PBS containing 0.05% Tween-20 (PBST) and blocked for
1 h at RT with PBST + 4% BSA (blocking buffer). Samples
and standards were diluted in blocking buffer, added to plate
and allowed to incubate at RT for 1 h. Rabbit anti-C3a was
diluted 1:4000 in blocking buffer and incubated for 1 h at RT.
HRP-conjugated donkey anti-rabbit IgG secondary was diluted
1:5000 in the same buffer and then incubated for 1 h at RT.
Following washing, tetramethylbenzidine (TMB) substrate was

Abbreviations: C3(H2 O), hydrolyzed form of C3; C3(MA), C3 treated with
methylamine to hydrolyze the thioester; iC3(H2 O), C3(H2 O) cleaved by factor I
in the presence of factor H, iC3(MA), C3(MA) cleaved by factor I in the presence
of factor H; f/t, freeze-thaw; pAb, polyclonal antibody; WB, Western blot; FB,
factor B; FI, factor I; FH, factor H; RT, room temperature; ICS, intracellular
complement system; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis;
AMR, antibody mediated rejection; BAL, bronchoalveolar lavage; NHS, normal
human serum.
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to evaluate the selectivity of the capture Ab. We confirmed that in
our assay the anti-C3b/iC3b capture Ab binds C3 methylamine
[C3(MA), a C3(H2 O) analog] and C3b/iC3b but not native C3
(Figure 2A) (23). The small amount of signal from purified C3
(open circle, Figures 2A,B) was likely from the trace quantity of
C3(H2 O) in the preparation and not from captured C3 (20, 23).
Since C3(H2 O) retains the C3a fragment which is lacking in
C3b/iC3b, we distinguished between these two proteins during
the detection step utilizing an anti-C3a pAb. The specificity of
the detection pAb for C3a-containing proteins was confirmed
as C3b was not identified (Figure 2B), although, as expected,
C3b was confirmed to be captured using the anti-C3 pAb for
detection (Figure 2A). Purified C3(MA) was used to prepare
a standard curve and establish that the sensitivity of the
assay ranges from 1.25 to 40 ng/ml (Figure 2B). C3(MA) was
selected as a surrogate for C3(H2 O) for the standard curve
because it has been established that it is conformationally and
functionally similar to C3(H2 O) (20, 25, 37). First, the C3(MA)
elution profile corresponds to C3(H2 O) in studies demonstrating
that C3 and C3(H2 O) can be separated by cation exchange
chromatography (37). Second, experiments in which C3 and
C3(H2 O) were purified from human serum demonstrated that
C3(MA) behaves similarly to C3(H2 O) in cellular uptake (20).
Further, treatment of C3 with KBr has been reported to result
in a conformational species corresponding to C3(H2 O) (25) and
we have used C3(KBr) in our ELISA with analogous results to
C3(MA) (Figure S1A).
Certain breakdown fragments of C3(H2 O) retain C3a
(Figure 2C). Consequently, if evaluating physiologic samples
such as human sera, there is a possibility that the C3(H2 O) levels
will be falsely elevated due to the presence of these fragments.
Thus, we evaluated whether the ELISA could also detect these
downstream fragments. We generated iC3(MA) and C3a-C3c
(see Methods) and confirmed conversion of the C3(MA) to
iC3(MA) and C3a-C3c by Western blot (Figures 2C; S1B). Using
these purified proteins in our ELISA, we demonstrated that
iC3(MA) is detected (Figure 2B); however, following cleavage
to C3a-C3c, binding is lost (Figure S2). Additionally, we
confirmed that C3a and C3c are not detected in the ELISA
(Figure S2). This indicates that only C3(H2 O) and iC3(H2 O)
will be detected in human samples and that downstream
degradation fragments, even those containing C3a, will not alter
C3(H2 O) measurements.

added. Following a 15 min incubation, the reaction was stopped
with 1 M phosphoric acid and absorbance read at 450 nM on a
uQuant plate reader (BioTek U.S., Winooski, VT).

Cofactor Assays
Cofactor assays were performed as previously described (26).
Briefly, in vitro cleavage of C3b and C3(MA) by FI in the presence
of the cofactor FH or sCR1 was performed by incubating 40 ng of
C3b or C3(MA) with 500 ng FH or sCR1 and 50 ng FI at 37◦ C for
30 min.

Western Blotting
Protein samples were electrophoresed under reducing conditions
in 4–20% SDS-PAG, transferred to nitrocellulose, and then
probed with rabbit anti-human C3a pAb or goat antihuman C3 pAb (Complement Technologies). This was followed
by appropriate HRP-conjugated secondary Abs. Blots were
visualized on a ChemiDoc XRS Imager (Bio-Rad).

Study Approval
Blood and BAL fluid were collected from healthy donors and
patients after written informed consent was obtained according
to the guidelines of the Washington University School of
Medicine Human Studies Committee. The SLE patient samples
are part of the cohort described in Kim et al. (27).

Statistics
All data were subjected to statistical analysis using Prism software
version 7 (GraphPad). Comparisons between two groups were
performed by 2-tailed t-test (parametric) or paired t-test
(non-parametric). Comparisons between multiple groups were
performed using a 1-way ANOVA with Bonferroni’s multiple
comparison test. A P < 0.05 was considered significant.

RESULTS
Development of an ELISA Specific
for C3(H2 O)
To determine if C3(H2 O) might serve as a disease biomarker
for conditions associated with complement activation as well
as to further evaluate the sample handling issues, we set out
to develop an ELISA specific for C3(H2 O) that lacks crossreactivity with C3, C3b or C3b fragments (Figure 1A). Antigenic
assays to quantitate C3 typically recognize both C3 and C3(H2 O)
(Figure 1A). Importantly, the hydrolysis of the internal thioester
bond is accompanied by a substantial conformational change
in C3(H2 O) such that it closely mimics the three-dimensional
structure of C3b (28–35) (Figure 1B). Accordingly, we designed
a C3(H2 O)-specific ELISA in which the capture antibody (Ab)
recognizes a conformationally-specific epitope in C3(H2 O) and
C3b, while the other Ab exclusively detects C3a (Figure 1C).
Thus, C3b and C3(H2 O) were separated from C3 during the
capture step and C3(H2 O) was distinguished from C3b by the
detection Ab being specific for the C3a domain (Figure 1C).
To confirm the specificity of the C3(H2 O) ELISA, we utilized
purified proteins to determine the selectivity of the capture and
detection Abs. A polyclonal anti-C3 detection Ab was employed
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ELISA Validation and Optimization in
Human Biospecimens
Matrix effects can occur when target antigen interacts with other
components in serum. To validate the use of the ELISA and
to ensure we could overcome potential inhibitory effects of
serum (matrix effects), we spiked in increasing concentrations of
C3(MA) to undiluted or 1:100 normal human serum (NHS) and
monitored recovery of the protein. In undiluted NHS, we did not
detect C3(H2 O). We also did not detect C3(MA) that is spiked
into the sample, indicating that undiluted NHS is inhibitory in
the ELISA; i.e., it causes a matrix effect. In contrast, at a 1:100
dilution of NHS, we fully detected the spiked in C3(MA). This

3

April 2019 | Volume 10 | Article 703

Elvington et al.

ELISA Specific for Human C3(H2O)

FIGURE 1 | C3(H2 O) ELISA set-up. (A) Schematic depicting C3, C3b, and C3(H2 O). (B) Diagram showing protein domains and the conformational rearrangement
following C3 activation to either C3b (with liberation of C3a) or C3(H2 O) (with a hydrolyzed thioester and retention of C3a). Note the movement of the ANA domain
(red) and the TED domain (dark blue). Diagram adapted from Janssen et al. (34, 35) and Gros et al. (36). (C) C3b and C3(H2 O) are recognized by the capture antibody
(3E7, mouse anti-C3b/iC3b). C3 is not captured. C3(H2 O) is recognized based on the presence of the C3a (ANA) domain in the detection step. MG1-8, macroglobulin
′
domains 1-8; LNK, linker domain; ANA, anaphylatoxin domain; α NT, n-terminus of the α-chain; CUB, complement C1r/C1s, UEGF, BMP1; TED, thioester-containing
domain; C345C, netrin (NTR) domain.

similar to one another (463.3 ± 51, 516.4 ± 52 ng/ml and 446.2
± 51 ng/ml C3(H2 O), respectively) (Figure 2E). In addition,
to further confirm specificity of the assay and to determine
how increased C3b/iC3b levels in samples might interfere with
measurements of C3(H2 O), we performed competition assays.
We found that 50% inhibition of the 40 ng/ml C3(H2 O) signal
occurred at 5500 ng/ml of C3b and 5000 ng/ml iC3b (Figure 2F).
The expected iC3b concentration in sera from an SLE patient
is 5.22-5.95 µg/ml (27), so the background iC3b concentration
at a 1:100 dilution typically used in this assay of ∼50-60 ng/ml
would have a negligible effect on the C3(H2 O) measurement.
Thus, interference by C3b or iC3b in serum is not likely to be
a concern for accurate C3(H2 O) measurements.

result validates the use of our ELISA for measuring C3(H2 O) in
human specimens and ensures the absence of inhibitory matrix
effects from serum at a 1:100 dilution (Figure 2D).
To further validate the ELISA, the inter- and intra- assay
precision was evaluated. First, we determined the inter-assay
variation, i.e., the variation between plates. Serum samples from 3
individuals were diluted 1:100 and 1:200 and assayed in triplicate
on 3 separate plates. The inter-assay coefficient of variation (%
CV) was calculated from the individual plate means (% CV 9.330;
Table 1). Next, we determined the intra-assay precision, i.e., the
variation between triplicates at 1:100 and 1:200 dilutions. The
intra-assay % CV was calculated from 18 samples measured in
triplicate and the average % CV was 5.849 (Table 2).
Prior determinations of C3(H2 O) in human samples have
been confounded by the inability to specifically distinguish
C3(H2 O) from C3 and C3 activation products. Thus, one major
goal of the C3(H2 O)-specific ELISA was to obtain a more
accurate measurement of human serum and plasma C3(H2 O)
levels. To demonstrate the utility of this assay for human
samples, we established baseline C3(H2 O) concentrations in
human serum and plasma from healthy donors that were
collected with different anticoagulants and analyzed immediately
after collection (i.e. never frozen). We found that C3(H2 O)
levels in human sera, EDTA-plasma and heparin plasma were

Frontiers in Immunology | www.frontiersin.org

Implications for Handling of
Human Specimens
Since sera are typically frozen prior to analysis, we also evaluated
C3(H2 O) levels in samples previously stored at −80◦ C. There
was an approximately four-fold increase in C3(H2 O) in serum
following one freeze/thaw (f/t) cycle compared to freshly isolated
(1,999 ± 111 vs. 463.3 ± 51; p < 0.0001; Figures 2E, 3A and
Table 3). Consistent with this result, freezing and thawing of
purified human C3 is reported to result in C3(H2 O) generation
and subsequent decrease of the hemolytic activity of complement
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FIGURE 2 | Specificity of the C3(H2 O) ELISA. (A) Binding comparison of proteins using anti-C3 pAb for detection. (B) Specificity of ELISA employing anti-C3a pAb.
C3(MA) and iC3(MA) are detected. (C) Schematic depicting the cleavage and inactivation of C3(H2 O) by cofactor proteins and the serine protease FI. Adapted from
Elvington et al. (20). (D) Increasing concentrations of C3(MA) were spiked into 1:100 NHS which had a baseline C3(H2 O) level of 938 ng/ml and protein recovery of the
C3(MA) over baseline was assessed by ELISA; n = 2, representative of 2 independent experiments. (E) C3(H2 O) was measured in human serum and plasma from
healthy adults; n = 3 donors (in duplicate, intra-assay precision; %CV 4.97). (F) Increasing quantity of purified C3b (red) or iC3b (blue) was incubated with 40 ng/ml
C3(MA) to assess if they compete for binding; n = 3.

To evaluate the possibility that C3(H2 O) was degraded (to
iC3(H2 O), for example), we ran WBs on the human sera that
had undergone multiple f/t cycles. Intact C3 α- and β-chains
were observed (Figure 3B), demonstrating that iC3(H2 O) was
indeed not being generated. Notably, at baseline, we do not detect
the α41 fragment (∼41 kDa) that is generated upon cleavage
of C3(H2 O) to iC3(H2 O), indicating that, although our assay
detects iC3(H2 O), the majority of what we are detecting in
serum samples is intact C3(H2 O) (Figure 3B, lanes 2-4). From
these data we concluded that the majority of C3(H2 O) in serum
samples, even when undergoing multiple f/t, is not in the form
of iC3(H2 O).
We also utilized the assay to examine C3(H2 O) generation in
healthy donors as this could facilitate a better understanding of
how samples should be handled in the research laboratory and
clinic. Our assay enabled us to revisit and quantitatively evaluate
C3 activation in serum and plasma, which is thought to occur
spontaneously and continuously at a low level (3–5). To evaluate
the rate of C3(H2 O) generation over time, healthy human donor
serum and plasma samples were incubated ex vivo for up to 22 h
at 4◦ C, room temperature (RT, 22◦ C) or 37◦ C. We did not detect
C3(H2 O) generation at 4◦ C, indicating that C3 in serum and
plasma was stable at this temperature. At RT and 37◦ C, however,
C3(H2 O) was generated in both human serum and plasma
(Figures 4A–C). Remarkably though, C3 is stable (minimal to no
C3(H2 O) generation) in EDTA- and heparin-plasma at 37◦ C for

TABLE 1 | Inter-assay precision.
1:100

1:200

P1

P2

P3

P1

P2

P3

Mean of Means

4,547

3,210

2,441

4,785

3,524

2,648

Std Dev of Means

363.6

301.3

117.8

897.1

226.3

227.8

% CV of Means

7.997

9.384

4.826

18.75

6.422

8.602

Inter-assay CV (n = 3) = 9.330; 7.402 (1:100); 11.258 (1:200)
Mean levels expressed in ng/ml.

(4). To more systematically evaluate this point in serum and
plasma (vs. purified C3), we performed increasing numbers of
f/t cycles on samples from healthy donors. Although there was
as expected (see above), an increase in C3(H2 O) content after a
single f/t, subsequent f/t cycles had less of an impact on C3(H2 O)
generation, with a lesser, but significant, increase from 1 f/t to
3 f/t cycles and no difference after 6 f/t cycles (Figure 3A and
Table 3). In contrast, we also evaluated generation of C3(H2 O)
from purified C3 and found that ∼25% of the C3 had converted
to C3(H2 O) following 6 f/t cycles (Figure S3A), consistent with
previous reports (4). Thus, C3 is stabilized against conversion
to C3(H2 O) in serum. These data indicate that interpretation
of results must be adjusted for sample handling conditions (i.e.,
fresh vs. frozen serum or plasma).

Frontiers in Immunology | www.frontiersin.org

5

April 2019 | Volume 10 | Article 703

Elvington et al.

ELISA Specific for Human C3(H2O)

2 h, demonstrating one advantage of plasma over serum. Notably,
the level of C3(H2 O) in serum incubated at 37◦ C is higher at
4 h compared to 24 h. We hypothesize that this decrease is due
to cleavage of the C3(H2 O) to fragments that are not detected
by our ELISA. This hypothesis is supported by the reduction
in the α-chain of C3 on WB at this timepoint (Figure 4E,
lane 11). Importantly, though, our results suggest that serum
samples may be stored at 4◦ C for up to at least 22 h without
C3(H2 O) generation.
Although we did not detect significant C3(H2 O) generation
after 1 h at RT in undiluted serum (above), we evaluated

generation of C3(H2 O) in diluted serum during the capture step
of the ELISA to confirm that this incubation step is not altering
C3(H2 O) measurements. This was accomplished by incubating a
1:100 dilution of NHS over a time course and then determining
C3(H2 O) concentration using a standard curve captured for the
equivalent amount of time. Standard curves captured for the
corresponding time was important to ensure that binding time
was not the reason for differences in C3(H2 O) measurements. In
1:100 NHS, we did not detect a significant increase in C3(H2 O)
generation over the 1 h capture time at RT, indicating that
samples are stable under these assay conditions (Figure S3B).
The increase in C3(H2 O) at elevated temperatures may also
drive accelerated production of C3 activation products. Using
WB, we found that the kinetics of iC3b/iC3(H2 O) (i.e presence
of C3 α43 and α41 fragments) appearance were similar to that
of C3(H2 O) generation, beginning at 22 h at RT (Figure 4D)
and 2 h at 37◦ C (b). This suggests that, like its generation,
inactivation of C3(H2 O) by Factors H and I occurs more
rapidly at 37◦ C. However, we do not detect the α24 band,
even upon overexposure of the WB, indicating that there is
no further cleavage to C3c (Figure S4). Since our ELISA also
detects iC3(H2 O), there is no evidence that breakdown affected
our detection of C3(H2 O) levels. Taken together, these studies
demonstrate the effectiveness of our assay using human samples
and provides guidance into how human specimens should
be handled and stored for C3(H2 O) and overall complement
measurements (see section Discussion).

TABLE 2 | Intra-assay precision.
Sample

Mean of triplicates

Standard deviation

% CV

1

4,681

55.5

1.186

2

4,180

111.0

2.656

3

3,047

183.1

6.010

4

3,276

289.0

8.823

5

2,497

18.5

0.7410

6

2,520

293.4

11.64

7

4,824

181.6

3.766

8

4,360

127.1

2.914

9

3,026

5.132

0.1696

10

3,578

287.5

8.036

11

2,521

87.43

3.468

12

2,911

176.5

6.063

13

4,135

293.5

7.098

14

5,816

1,034

17.78

15

3,558

257.4

7.236

16

3,719

473.2

12.72

17

2,306

69.34

3.007

Healthy control

18

2,513

49.67

1.976

SLE patient

TABLE 3 | C3(H2 O) levels in healthy controls (HC) and SLE patient sera.
Fresh serum
463 (±51)
ND

1 f/t

3 f/t

1,999 (±111)**** 2,630 (±205)π
3,399 (±538)**

6 f/t
2,480 (±381)

5,698 (±676)# 7,192 (±1090)*

Mean C3(H2 O) level in ng/ml ± SE. ND= no data. F/T = Freeze/thaw. n=3-6 (3 HC, 6
SLE); **** p <0.0001 vs. fresh serum; **p < 0.01 vs. healthy control; π p < 0.01 vs. healthy
control 1 f/t; # p < 0.0001 vs. SLE 1 f/t; * p < 0.05 vs. SLE 3 f/t.

Intra-assay CV (n-=18; 6/plate) = average % CV = 5.849
Mean levels expressed in ng/ml.

FIGURE 3 | Effect of freeze/thaw cycles on C3(H2 O) generation. (A) Samples were subjected to 1, 3 or 6 freeze/thaw (f/t) cycles and the C3(H2 O) content was
measured; n = 3, **p < 0.01. (B) C3 cleavage was assessed by WB in serum subjected to increasing f/t cycles. No evidence of C3(H2 O) degradation is observed.
Notably, the sensitivity of the WB is ∼10 ng and even an over-exposure fails to show additional bands.
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FIGURE 4 | Effect of time and temperature on C3(H2 O) generation in serum and plasma. Samples were incubated for the indicated time at 4◦ C (A), 22◦ C (B) or 37◦ C
(C) and then stored at −80◦ C prior to analysis; n=3 healthy donors. C3(H2 O) generation (i.e., tickover) does not occur up to 22 h at 4◦ C, occurs minimally over 4 h at
RT, but occurs more rapidly (particularly in serum) at 37◦ C. Serum samples incubated at RT (D) or 37◦ C (E) were diluted 1:500 and assessed for C3 breakdown by
WB under reducing conditions with a goat anti-C3 pAb. Note that we routinely detect low level contamination of C3 dimers in all purified C3 preps and sera samples
that we evaluate by WB. Dimers are indicated in figure.

C3(H2 O) Levels Are Increased in SLE and
RA Sera

that the potential for C3 turnover is higher in SLE and RA
patients compared to healthy donors. Since there is a higher
concentration of C3(H2 O) in SLE serum compared to healthy
controls, we confirmed by WB that in SLE samples the majority is
in the form of C3(H2 O), not iC3(H2 O) (Figure 5D). These data
support the possibility that C3(H2 O) may serve as a biomarker in
SLE and RA.

Having established the specificity, sensitivity and sample
handling conditions for the C3(H2 O) ELISA, we next desired
to evaluate the diagnostic utility of this assay. Thus, levels
of C3(H2 O) were measured in serum from patients with
autoantibody-associated diseases where complement activation is
known to occur (38–40). These samples and the corresponding
healthy donor samples had all been stored at −80◦ C prior
to analysis. We found an increase in C3(H2 O) levels in
patients with active SLE (3,098 ± 382 ng/ml) and RA (4,234
± 955 ng/ml) compared to healthy controls (HC; 1,999 ±
111 ng/ml) (Figure 5A), suggesting modestly higher baseline
levels in patients’ serum in these two disease states.
Since we did not detect significant increases in C3(H2 O)
generation in healthy donors after the initial f/t cycle (Figure 3A),
we hypothesized that this would also be true utilizing
autoimmune patient samples. Instead, we found that C3(H2 O)
increased in serum samples from SLE patients with each f/t
cycle (Figure 5B and Table 3), establishing that the rates of
C3(H2 O) generation are increased in SLE sera. To confirm this
observation, we incubated sera from healthy control, RA and
SLE patients ex vivo at RT or 37◦ C for 6 h. The difference in
C3(H2 O) levels following incubation was much greater than
the baseline differences, with an accelerated rate of C3(H2 O)
generation in SLE and RA patients (Figure 5C). This indicates

Frontiers in Immunology | www.frontiersin.org

C3(H2 O) Levels in BAL Fluid From Lung
Transplant Recipients
We also wanted to determine whether increased C3(H2 O) levels
could be observed in other complement-mediated conditions
featuring local, rather than systemic, complement activation.
Thus, we examined C3(H2 O) levels in bronchoalveolar lavage
(BAL) fluid samples obtained from lung transplant recipients
either more than 3 months prior to antibody-mediated rejection
(AMR) diagnosis or within 3 months of this diagnosis. We found
a significant increase in C3(H2 O) in the BAL fluid obtained
within 3 months prior to AMR compared to BAL samples
obtained further from diagnosis (Figure 5E; 2,091 ± 398 vs. 248.3
± 60 ng/ml; p < 0.005). Additionally, we evaluated sequential
BAL specimens from lung transplant recipients who developed
AMR to compare C3(H2 O) changes in individual patients. In
6 of 8 patients, C3(H2 O) level increased in the BAL fluid
within 3 months prior to AMR diagnosis (Figure 5F). These
data strongly support the potential utility of clinically evaluating
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FIGURE 5 | C3(H2 O) is elevated in complement-mediated conditions. (A) C3(H2 O) levels were measured in serum samples from RA and SLE patients and compared
to serum from healthy donors. All samples had been stored at −80◦ C prior to evaluation; n=5 (in duplicate; intra-assay precision, %CV 5.59). (B) Serum from SLE
patients were subjected to 1, 3, or 6 f/t cycles prior to measuring C3(H2 O) levels; n = 3. (C) Serum from healthy donors (n = 6) or patients with SLE (n = 4) or RA
(n=5) were incubated at RT or 37◦ C for 6 h before C3(H2 O) was measured; samples in duplicate. SLE at 22◦ C, ***p < 0.0005 vs. healthy control; RA at 22◦ C, SLE
and RA at 37◦ C, ****p < 0.0001 vs. healthy control. (D) Serum from SLE patients (n = 4) was diluted 1:500 and assessed for C3(H2O) breakdown by WB under
reducing conditions with a goat anti-C3 pAb. (E) C3(H2 O) levels were measured in BAL fluid samples from lung transplant recipients either >3 months prior to
diagnosis (n = 10) or within 3 months of diagnosis of AMR (n = 22), **p < 0.005 by student’s t-test. (F) C3(H2 O) levels were measured in sequential BAL fluid samples
in 8 patients who had paired specimens. Lines connect sequential samples from the same patient; **p < 0.01 by paired t-test. HC, healthy control; SLE, systemic
lupus erythematous; RA, rheumatoid arthritis.

analysis of the effects of temperature and freeze-thawing on
C3(H2 O) generation in serum and plasma samples; and 3) three
examples of diseases in which C3(H2 O) measurements may
inform on disease pathogenesis and/or serve as a diagnostic or
prognostic biomarker.
In fresh serum and heparinized- or EDTA-treated plasma
samples from healthy donors, the concentration of C3(H2 O) was
∼500 ng/ml, a value lower than the 10-20 µg/ml that would have
been predicted from previous reports demonstrating 1–2% of
purified C3 turning over per hour (4, 5). There was no statistical
difference in C3(H2 O) levels between serum or the two types of
plasma. However, if either the serum or plasma samples were
frozen once the C3(H2 O) levels increased 3- to 4-fold. Further, in
contrast to our expectations, subsequent freeze-thaw cycles (up
to 6x) had a lesser influence on the C3(H2 O) concentration: thus,
it was not proportionally generated by repetitively freezing and
thawing of the samples which may have been expected from the
literature (4). The effect of temperature was also studied. Notably,
maintaining the sample at 4◦ C led to no further generation of
C3(H2 O) for up to 22 hrs. In contrast, at 37◦ C or 22◦ C C3(H2 O)
levels began to increase at 2 or 4 h of storage, respectively.
One explanation for the apparent discrepancy in C3(H2 O)
levels between this study and previous work is that we have serum
or plasma instead of purified C3 in aqueous solution. In our assay
system, we demonstrate a rather dramatic (∼100- fold) difference

C3(H2 O) levels in the BAL as a both a diagnostic and, more
importantly, a putative prognostic biomarker of AMR. They
further demonstrate the potential utility of the assay to quantify
C3(H2 O) in human fluids beyond serum and plasma.

DISCUSSION
C3(H2 O), described nearly 40 years ago as the key form of C3
triggering alternative pathway activation (3–5, 41), has remained
somewhat of an enigma as to how it is generated in vivo
and, particularly, its potential importance in a clinical setting.
Also, the recent discoveries of an intracellular complement
system (11) and a C3(H2 O) cellular recycling pathway (20)
have reinvigorated interest in this distinct form of C3, especially
relative to defining its utility as a biomarker and initiator of
complement activation. While clinical assays exist for C3 and
certain of its fragments (C3a, iC3b and C3d), currently there
is no sensitive and straight-forward assay available to measure
C3(H2 O). In this report, we provide such an assay and further
hypothesize that C3(H2 O) is a previously underappreciated
player in autoimmunity and inflammatory diseases whose
measurement may serve as a biomarker. In this manuscript,
utilizing a specific and sensitive assay for C3(H2 O), we provide:
1) data on which one can form guidelines for handling of
human biospecimens for complement measurements; 2) an
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that modulates key cytokines (17) and promotes cell survival
(45), may provide a better understanding of etiopathology
of certain inflammatory disease and lead to more effective
treatment options.
Although the mechanism of accelerated C3(H2 O) generation
in SLE and RA is unknown, we hypothesize that augmented
inherent instability in the patients’ C3 protein driven by the
presence of a proinflammatory environment and damaged or
injured cellular tissues is at the basis of pathogenesis. To that
end, our assay will allow quantification of C3(H2 O) in both
in vitro and in vivo systems to better understand its role and
mechanism of generation. Using our SLE cohort (27), we plan
to study C3(H2 O) in those patients with low complement, active
vs. inactivate disease, and varying severity of organ involvement.
Our goal is to assess these and multiple other aspects relative to
the requirements in vivo for C3(H2 O) generation. We will utilize
this assay to better understand how complement activation drives
diseases pathogenesis and severity and whether it can be used as
a diagnostic biomarker. Additionally, these data do not rule out
that C3(H2 O) may also be a marker of disease activity in SLE
and we will explore this and other possibilities in our SLE patient
cohort (27) in the future.
We also wanted to determine whether increased C3(H2 O)
levels could be observed in other complement-mediated
conditions featuring local, rather than systemic, complement
activation. Acute antibody-mediated rejection (AMR) is a
rare and often fatal complication that occurs following lung
transplantation (46, 47). AMR is associated with objective
measurements of allograft dysfunction (decline in lung function,
infiltrates on x-rays, histopathological changes on biopsy), which
can present with or without symptoms. AMR is defined as
allograft dysfunction in the presence of donor-specific antibodies
to HLA (DSA) along with positive histology suggestive of
AMR (such as neutrophil margination, capillaritis, organizing
pneumonia, and /or lung injury) and positive C4d staining (47).
However, not all patients present as “definite clinical” AMR;
some may lack all of these features, and in some, C4d staining
can be negative (48). Moreover, while the presence of DSA in
asymptomatic patients is a risk factor for AMR, there is no
predictive biomarker for this condition, especially one that can
be obtained without an invasive transbronchial biopsy (47).
Our results suggest that C3(H2 O) increases in the BAL fluid
of lung transplant recipients prior to the development AMR.
While complement activation has been connected with AMR
(46, 47, 49), C4d staining in lung of AMR patients is neither
sensitive nor specific, and an entity of C4d-negative AMR is
also increasingly appreciated (48). Moreover, C4d staining needs
a biopsy to be performed, and is most likely to be positive
around the time of AMR diagnosis. Hence, further evaluating
a biomarker that does not need a biopsy to be performed
should be of interest to the transplant community. In future
studies, our assay can be used to determine if these C4dnegative cases are truly mediated by a pathological process that
is independent of complement activation; or whether C3(H2 O)
would be a more specific and non-invasive biomarker compared
to C4d staining (50, 51). Thus, our results prompt not only
the potential use of C3(H2 O) as a biomarker for AMR but

in C3(H2 O) formation by purified C3 in aqueous buffer vs. C3
in plasma or serum following freeze-thaw cycles (Figure S3A).
Purified C3 (in the presence of factors B, D, H, and I) is reported
to be inactivated at a rate of 1–2%/h at 37◦ C (4, 5). In the
absence of additional serum factors (i.e., purified C3 alone in
buffer), the generation of C3(H2 O) was reported to occur at 0.2–
0.4%/h (4, 5). In line with these previous observations, C3(H2 O)
was generated in serum or plasma incubated at 37◦ C at ∼0.3–
0.5%/h, although this was not linear at longer time points. We
hypothesize that the lack of linearity is due to either regulation by
FH at higher concentrations of C3(H2 O) or degradation by other
proteases. This is consistent with the previous reports showing
C3 inactivation at 1–2%/h in the presence of additional serum
factors (3, 4). Additionally, the binding site for FH in C3(H2 O) is
not exposed immediately due to the slow conformation change
of this protein (7) and this may explain the observation of
delayed regulation of the C3(H2 O) by FH in our system. A more
comprehensive understanding of C3(H2 O) regulation is an active
focus of our laboratory.
One goal of our study was to better understand and thereby
provide further guidance as to how human samples should be
handled in the research laboratory and clinic for complement
measurements. We note that previous work suggests that
C3(H2 O) generation occurs due to contact activation [reviewed
in (42)] and therefore incubating serum and plasma in tubes, as
we have in our experiments, does not reflect in vivo generation
of C3(H2 O). However, human biospecimens are stored this
way both in the laboratory and in the clinic so our data are
instructive relative to the handling and storage of samples
and the interpretation of data from patient-derived specimens,
where complement activation and turnover may be playing a
role. Specifically, our results provide guidelines for a suitable
short-term storage temperature for human serum or plasma
prior to clinical testing or investigative experiments in the
laboratory setting.
Our data also support the assessment of C3(H2 O) generation
as a biomarker for the presence of autoantibody-mediated
diseases. Identifying such a biomarker that may be tied to the
underlying pathogenesis would also fill a significant unmet need
in the evaluation of patients with autoimmune diseases. Since C3
levels in blood are altered in SLE, it may be more instructive to
express the C3(H2 O) level as a ratio of total C3 (27). Regardless,
C3(H2 O) generation is enhanced in SLE and RA patients and
we will explore in detail the reasons in our patient cohorts in
the future.
The observed differences in C3(H2 O) generation may
represent a fundamental variation in C3 metabolism in SLE
and other diseases featuring complement activation. The two
major consequences of a complement system deficiency are
bacterial infections and autoimmunity (particularly SLE) (38,
43). In acute injury states leading to membrane damage,
apoptosis and necrosis, the complement system plays an
important role in the host’s response to “altered self ” (44).
The function of C3(H2 O) in these processes is unclear and has
not been specifically investigated. However, the discovery of an
intracellular complement system (11), including the observations
that C3(H2 O) uptake is a major source of intracellular C3 (20)
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complement activation that would disclose novel therapeutic
targets. Notably, the commercial availability of the antibodies
required to set-up this ELISA make it easily adoptable by
any interested lab. Additionally, our data using the C3(H2 O)
ELISA suggests that C3(H2 O) in the plasma should be
further rigorously evaluated as a promising biomarker for
SLE and in the lungs, as a prognostic indicator in lung
transplant recipients at an increased risk for developing acute
antibody-mediated rejection.

also investigating C3(H2 O) development and function to better
understand mechanisms driving AMR.
As our study points out, it is critical to understand proper
sample handling and to utilize the appropriate comparator
(i.e., frozen vs. fresh healthy control serum) when interpreting
the C3(H2 O) content of patient samples. Additionally, studies
by Pangburn et al (37) have demonstrated the presence of a
C3(H2 O) intermediate, designated C3(N)∗ , that has not adopted
the C3b-like final conformational state of C3(H2 O) (25, 37).
This intermediate would not be detected by our ELISA, since
it recognizes only the final conformational state C3(H2 O). We
plan to better understand the potential impact of C3(N)∗ on
the interpretation of the results of the C3(H2 O) assay in human
biospecimens. For example, whether this C3(N)∗ is one of the
reasons for the 3 to 4x increase in C3(H2 O) associated with
one freeze-thaw or the increased generation observed in SLE
and RA samples remains to be investigated. The functional role
and relevance of this intermediate to human disease is also
under investigation.
While an ELISA has been previously described to quantitate
C3(H2 O), the mAb utilized had higher specificity to C3a (21, 22).
This was an inherent limitation for the assay to specifically
quantify C3(H2 O), as the presence of C3a in a sample would
interfere with the detection of C3(H2 O) in this ELISA. In the
ELISA described herein, we detect only C3(H2 O) and its cleavage
fragment iC3(H2 O) and are able to exclude the effects of C3a,
C3b, iC3b, C3c, C3dg, or C3d on measurements. The additional
C3(H2 O) cleavage fragment that we do measure, iC3(H2 O),
would be generated by cofactor activity. However, when we
assessed this possibility, the large majority of protein we detected
in serum and plasma from healthy controls and SLE patients
was C3(H2 O), not its degradation product iC3(H2 O). Thus, this
C3(H2 O) ELISA provides an opportunity to investigate the role
of C3(H2 O) in mediating complement activity in human health
and disease.
In summary, we have developed and characterized an ELISA
that is specific for human C3(H2 O). The role of C3(H2 O)
in autoimmunity and inflammation has not been thoroughly
investigated in part because of difficulty of measuring it
quantitatively in human fluids. The C3(H2 O) ELISA represents
a tool to allow for further analysis of the role of C3(H2 O)
in human autoimmune and inflammatory diseases. It also
could assist in the identification of intracellular pathways of
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